ABSTRACT
BACKGROUND AND AIMS: Dietary quality affects cardiometabolic risk, yet its pathways of influence on regional adipose tissue depots involved in metabolic and diabetes risk are not well established. We aimed to investigate the relationship between dietary quality and regional adiposity. METHODS AND RESULTS: We investigated 5079 individuals in the Multi-Ethnic Study of Atherosclerosis (MESA) who had food-frequency questionnaires and measurement of pericardial fat and hepatic attenuation at the baseline study visit in MESA, as well as a subgroup with imaging for visceral and subcutaneous fat (N = 1390). A dietary quality score (DietQuality) was constructed to include established food group constituents of a Mediterranean-type diet. Linear models estimated associations of dietary score as well as its constituents with regional adiposity. Baseline mean age was 61 (± 10) years, and approximately half of the participants (47%) were male. Those with a higher DietQuality score were generally older, female, with a lower body mass index, C-reactive protein, and markers of insulin resistance. After adjustment, a higher DietQuality score was associated with lower visceral fat (lowest vs. highest dietary score quartile: 523.6 vs. 460.5 cm(2)/m; P < 0.01 for trend), pericardial fat (47.5 vs. 41.3 cm(3)/m; P < 0.01 for trend), lesser hepatic steatosis (by hepatic attenuation; 58.6 vs. 60.7 Hounsfield units; P < 0.01 for trend), but not subcutaneous fat (P = 0.39). Greater fruits, vegetables, whole grains, seeds/nuts and yogurt intake were associated with decreased adiposity, while red/processed meats were associated with greater regional adiposity. CONCLUSION: A higher quality diet pattern is associated with less regional adiposity, suggesting a potential mechanism of beneficial dietary effects on diabetes, metabolic, and cardiovascular risk.
Subject(s)
Atherosclerosis/prevention & control , Body Fat Distribution , Diet, Healthy , Diet, Mediterranean , Aged , Biomarkers/blood , Body Mass Index , Body Weight , C-Reactive Protein/metabolism , Cholesterol, HDL/blood , Cholesterol, LDL/blood , Cross-Sectional Studies , Ethnicity , Female , Humans , Insulin Resistance , Intra-Abdominal Fat/metabolism , Male , Middle Aged , Nutrition Assessment , Risk Factors , Socioeconomic Factors , Subcutaneous Fat/metabolism , Surveys and Questionnaires , Triglycerides/blood , Waist CircumferenceABSTRACT
BACKGROUND AND AIMS: Many US adults use calcium supplements to address inadequate dietary intake and improve bone health. However, recent reports have suggested that use of calcium supplements may elevate cardiovascular disease (CVD) risk. In this study, we examined associations between baseline calcium supplement use and incident myocardial infarction (MI) (n = 208 events) and CVD events (n = 641 events) over 10.3 years in men and women from the Multi-Ethnic Study of Atherosclerosis (MESA) cohort (n = 6236), with dietary calcium intake at baseline also examined as a supplementary objective. METHODS AND RESULTS: Using Cox proportional hazards models, no compelling associations between calcium intake from supplements or diet and incident CVD events were observed upon multivariate adjustment for potential confounders. An association with lower MI risk was observed comparing those with low levels of calcium supplement use (1-499 mg) to those using no calcium supplements (hazard ratio 0.69, 95% CI 0.48, 0.98, p = 0.039). Relationships were homogeneous by gender, race/ethnicity, or chronic kidney disease. Results were also similar when the analysis was limited to postmenopausal women only. CONCLUSION: Analysis of incident MI and CVD events in the MESA cohort does not support a substantial association of calcium supplement use with negative cardiovascular outcomes.
Subject(s)
Calcium/administration & dosage , Cardiovascular Diseases/epidemiology , Dietary Supplements , Aged , Aged, 80 and over , Calcium/adverse effects , Calcium, Dietary/administration & dosage , Cardiovascular Diseases/diagnosis , Cardiovascular Diseases/prevention & control , Cohort Studies , Dietary Supplements/adverse effects , Female , Humans , Incidence , Linear Models , Logistic Models , Male , Middle Aged , Multivariate Analysis , Myocardial Infarction/epidemiology , Postmenopause , Proportional Hazards Models , Protective Factors , Risk Assessment , Risk Factors , Time Factors , United States/epidemiologyABSTRACT
OBJECTIVE: Low-density lipoprotein-related receptor protein 1 (LRP1) is a multi-functional endocytic receptor and signaling molecule that is expressed in adipose and the hypothalamus. Evidence for a role of LRP1 in adiposity is accumulating from animal and in vitro models, but data from human studies are limited. The study objectives were to evaluate (i) relationships between LRP1 genotype and anthropometric traits, and (ii) whether these relationships were modified by dietary fatty acids. DESIGN AND METHODS: We conducted race/ethnic-specific meta-analyses using data from 14 studies of US and European whites and 4 of African Americans to evaluate associations of dietary fatty acids and LRP1 genotypes with body mass index (BMI), waist circumference and hip circumference, as well as interactions between dietary fatty acids and LRP1 genotypes. Seven single-nucleotide polymorphisms (SNPs) of LRP1 were evaluated in whites (N up to 42 000) and twelve SNPs in African Americans (N up to 5800). RESULTS: After adjustment for age, sex and population substructure if relevant, for each one unit greater intake of percentage of energy from saturated fat (SFA), BMI was 0.104 kg m(-2) greater, waist was 0.305 cm larger and hip was 0.168 cm larger (all P<0.0001). Other fatty acids were not associated with outcomes. The association of SFA with outcomes varied by genotype at rs2306692 (genotyped in four studies of whites), where the magnitude of the association of SFA intake with each outcome was greater per additional copy of the T allele: 0.107 kg m(-2) greater for BMI (interaction P=0.0001), 0.267 cm for waist (interaction P=0.001) and 0.21 cm for hip (interaction P=0.001). No other significant interactions were observed. CONCLUSION: Dietary SFA and LRP1 genotype may interactively influence anthropometric traits. Further exploration of this, and other diet x genotype interactions, may improve understanding of interindividual variability in the relationships of dietary factors with anthropometric traits.
Subject(s)
Black People , Fatty Acids/metabolism , Low Density Lipoprotein Receptor-Related Protein-1 , Obesity/genetics , Polymorphism, Single Nucleotide , White People , Adipose Tissue , Adult , Aged , Aged, 80 and over , Black People/genetics , Body Mass Index , Europe/epidemiology , Female , Gene Frequency , Gene-Environment Interaction , Genetic Predisposition to Disease , Genotype , Humans , Low Density Lipoprotein Receptor-Related Protein-1/genetics , Low Density Lipoprotein Receptor-Related Protein-1/metabolism , Male , Middle Aged , Obesity/epidemiology , Phenotype , Prevalence , United States/epidemiology , White People/geneticsABSTRACT
As a peroxisome proliferator-activated receptor alpha (PPARα) agonist, fenofibrate favorably modulates dyslipidemia and inflammation markers, which are associated with cardiovascular risk. To determine whether variation in the PPARα receptor gene was associated with lipid and inflammatory marker response, we conducted a 3-week trial of fenofibrate in 861 men and women. Mixed linear models that controlled for age and sex, as well as family pedigree and study center, were constructed using single-nucleotide polymorphisms (SNPs) in the PPARα gene as predictors and changes in fasting triglycerides (TGs), cholesterol and inflammatory markers as outcomes. Significant associations with low-density cholesterol and interleukin-2 (P<0.001) responses to fenofibrate were found. Although there were suggestive associations with tumor necrosis factor-alpha and TG responses (P<0.05), these did not survive the correction for multiple testing. We conclude that variants in the PPARα gene may contribute to future pharmacogenomic paradigms seeking to predict fenofibrate responders from both an anti-dyslipidemic and anti-inflammatory perspective.
Subject(s)
Cholesterol, LDL/genetics , Fenofibrate/administration & dosage , Lipids/genetics , PPAR alpha/genetics , Adult , Aged , Cholesterol, LDL/blood , Female , Genetic Association Studies , Humans , Lipids/blood , Male , Middle Aged , Polymorphism, Single Nucleotide , Triglycerides/blood , Triglycerides/genetics , Tumor Necrosis Factor-alpha/geneticsABSTRACT
BACKGROUND: Increased reaction time variability (RTV) on cognitive tasks requiring a speeded response is characteristic of several psychiatric disorders. In attention deficit hyperactivity disorder (ADHD), the association with RTV is strong phenotypically and genetically, yet high RTV is not a stable impairment but shows ADHD-sensitive improvement under certain conditions, such as those with rewards. The state regulation theory proposed that the RTV difference score, which captures change from baseline to a rewarded or fast condition, specifically measures 'state regulation'. By contrast, the interpretation of RTV baseline (slow, unrewarded) scores is debated. We aimed to investigate directly the degree of phenotypic and etiological overlap between RTV baseline and RTV difference scores. Method We conducted genetic model fitting analyses on go/no-go and fast task RTV data, across task conditions manipulating rewards and event rate, from a population-based twin sample (n=1314) and an ADHD and control sibling-pair sample (n=1265). RESULTS: Phenotypic and genetic/familial correlations were consistently high (0.72-0.98) between RTV baseline and difference scores, across tasks, manipulations and samples. By contrast, correlations were low between RTV in the manipulated condition and difference scores. A comparison across two different go/no-go task RTV difference scores (slow-fast/slow-incentive) showed high phenotypic and genetic/familial overlap (r = 0.75-0.83). CONCLUSIONS: Our finding that RTV difference scores measure largely the same etiological process as RTV under baseline condition supports theories emphasizing the malleability of the observed high RTV. Given the statistical shortcomings of difference scores, we recommend the use of RTV baseline scores for most analyses, including genetic analyses.
Subject(s)
Attention Deficit Disorder with Hyperactivity/genetics , Reaction Time/genetics , Twins/genetics , Adolescent , Attention Deficit Disorder with Hyperactivity/psychology , Case-Control Studies , Child , Female , Humans , Inhibition, Psychological , Male , Models, Genetic , Phenotype , Reaction Time/physiology , Twins/psychology , Twins, Dizygotic/genetics , Twins, Dizygotic/psychology , Twins, Monozygotic/genetics , Twins, Monozygotic/psychologyABSTRACT
BACKGROUND AND AIMS: In vitro studies suggest that low density lipoprotein receptor-related protein 1 (LRP1) plays a role in the secondary uptake of chylomicrons. In addition, in vivo studies using LRP-1 knockout mice show these animals exhibit delayed chylomicron clearance. Whether this is true in humans is unknown. We aimed to determine whether genetic variants in LRP-1 are associated with postprandial chylomicron uptake in humans given an oral fat challenge. METHODS AND RESULTS: As many as 817 men and women (mean age +/- standard deviation = 48.4 +/- 16.4 years) forming the study population for the Genetics of Lipid Lowering Drugs Network (GOLDN) study ingested an oral fat load of 700 kilocalories per m² of body surface area at 83% fat, after an 8-h fast. Chylomicrons were measured by nuclear resonance spectroscopy (NMR) at fasting, and 3.5 and 6 h after the meal. 26 Single nucleotide polymorphisms (SNPs) in the LRP-1 gene were genotyped on the Affymetrix 6.0 array. Chylomicrons were, as expected, zero at fasting. Mixed linear models adjusted for age, sex, study site and pedigree tested for associations between LRP-1 SNPs and changes in chylomicron concentrations 3.5-6 h. A gene-based test across all 26 SNPs was conducted which corrected for the linkage disequilibrium (LD) between SNPs. 11 LRP-1 SNPs were significantly associated with the change in chylomicron concentration correction for multiple testing (Q < 0.05). The subsequent gene-based test, was also significant (P = 0.01). CONCLUSION: These results require replication but strongly indicate the role of LRP1 in postprandial lipoprotein uptake and/or clearance.
Subject(s)
Chylomicrons/metabolism , Diet, High-Fat/adverse effects , Dietary Fats/metabolism , Intestinal Absorption , Low Density Lipoprotein Receptor-Related Protein-1/genetics , Meals , Polymorphism, Single Nucleotide , Adult , Alleles , Chylomicrons/blood , Female , Genetic Association Studies , Humans , Linkage Disequilibrium , Low Density Lipoprotein Receptor-Related Protein-1/metabolism , Magnetic Resonance Spectroscopy , Male , Middle Aged , Minnesota , Oligonucleotide Array Sequence Analysis , Postprandial Period , UtahABSTRACT
BACKGROUND AND AIMS: Adiponectin is an adipose-secreted protein that has been linked to changes in insulin sensitivity, high-density lipoprotein cholesterol levels, and inflammatory patterns. Although fenofibrate therapy can raise adiponectin levels, treatment response is heterogeneous and heritable, suggesting a role for genetic mediators. This is the first genome-wide association study of fenofibrate effects on circulating adiponectin. METHODS AND RESULTS: Plasma adiponectin was measured in participants of the Genetics of Lipid Lowering Drugs and Diet Network (n = 793) before and after a 3-week daily treatment with 160 mg of fenofibrate. Associations between variants on the Affymetrix Genome-Wide Human SNP Array 6.0 and adiponectin were assessed using mixed linear models, adjusted for age, sex, site, and family. We observed a statistically significant (P = 5 × 10â»8) association between rs2384207 in 12q24, a region previously linked to several metabolic traits, and the fenofibrate-induced change in circulating adiponectin. Additionally, our genome-wide analysis of baseline adiponectin levels replicated the previously reported association with CDH13 and suggested novel associations with markers near the PCK1, ZBP1, TMEM18, and SCUBE1 genes. The findings from the single marker tests were corroborated in gene-based analyses. Biological pathway analyses suggested a borderline significant association between the EGF receptor signaling pathway and baseline adiponectin levels. CONCLUSIONS: We present preliminary evidence linking several biologically relevant genetic variants to adiponectin levels at baseline and in response to fenofibrate therapy. Our findings provide support for fine-mapping of the 12q24 region to investigate the shared biological mechanisms underlying levels of circulating adiponectin and susceptibility to metabolic disease.
Subject(s)
Adiponectin/blood , Cadherins/genetics , Chromosomes, Human, Pair 12 , Drug Resistance , Fenofibrate/pharmacology , Hypolipidemic Agents/pharmacology , Polymorphism, Single Nucleotide , Adiponectin/metabolism , Adipose Tissue, White/drug effects , Adipose Tissue, White/metabolism , Adult , Cadherins/metabolism , Female , Gene Frequency , Genome-Wide Association Study , Humans , Linkage Disequilibrium , Male , Middle Aged , Minnesota , Oligonucleotide Array Sequence Analysis , Siblings , UtahABSTRACT
Many twin studies on parental ratings of attention deficit hyperactivity disorder (ADHD) symptoms report low or negative DZ correlations. The observed differences in MZ and DZ variances indicate sibling contrast effects, which appear to reflect a bias in parent ratings. Knowledge of the factors that contribute to this rater contrast effect is, however, limited. Using parent-rated ADHD symptoms from the Twins' Early Development Study and a novel application of a twin model, we explored a range of socio-demographic variables (ethnicity, socio-economic status, and family size), as potential contributors to contrast effects and their interactive effect with gender composition of twin pairs. Gender did moderate contrast effects but only in DZ opposite-sex twin pairs. Family size also showed a moderating effect on rater contrast effects, which was further modified by gender. We further observed an effect of rating scale, with the DSM-IV ADHD subscale of the Revised Conners' Parent Rating Scale more resistant to contrast effects than shorter scales of ADHD symptoms. The improved identification of situations where the accuracy of the most common informant of childhood ADHD symptoms-parents-is compromised as a result of rater bias, might have implications for future research on ADHD.